

PERSPECTIVE

Biomarkers for dementia in Latin American countries: Gaps and opportunities

Mario A. Parra¹ | Paulina Orellana^{2,3} | Tomas Leon^{4,5} | Cabello G. Victoria^{2,6,7} |
 Fernando Henriquez^{6,8,9} | Rodrigo Gomez^{5,10} | Constanza Avalos^{2,3} |
 Andres Damian¹¹ | Andrea Slachevsky^{5,6,8,12} | Agustin Ibañez^{2,3,4,13,14} |
 Henrik Zetterberg^{15,16,17,18,19} | Betty M. Tijms²⁰ | Jennifer S. Yokoyama^{13,21} |
 Stefanie D. Piña-Escudero²² | J. Nicholas Cochran²³ | Diana L. Matallana^{24,25,26} |
 Daisy Acosta²⁷ | Ricardo Allegri^{28,29} | Bianca P. Arias-Suárez³⁰ | Bernardo Barra^{31,32} |
 Maria Isabel Behrens^{12,33,34,35} | Sonia M. D. Brucki³⁶ | Geraldo Busatto³⁷ |
 Paulo Caramelli³⁸ | Sheila Castro-Suarez^{22,39} | Valeria Contreras⁴⁰ |
 Nilton Custodio⁴¹ | Sergio Dansilio⁴² | Myriam De la Cruz-Puebla^{13,43,44,45} |
 Leonardo Cruz de Souza^{37,46} | Monica M. Diaz^{47,48} | Lisette Duque⁴⁹ |
 Gonzalo A. Farías³³ | Sergio T. Ferreira⁵⁰ | Nahuel Magrath Guimet^{22,28} |
 Ana Kmaid⁵¹ | David Lira⁴¹ | Francisco Lopera⁵² | Beatriz Mar Meza^{22,53} |
 Eliane C. Miotto³⁶ | Ricardo Nitrini³⁶ | Alberto Nuñez⁴⁹ | Santiago O'Neill⁵⁴ |
 John Ochoa⁵⁵ | Maritza Pintado-Caipa^{22,41} | Elisa de Paula França Resende^{13,38,46,56,57} |
 Shannon Risacher⁵⁸ | Luz Angela Rojas⁵⁹ | Valentina Sabaj⁶⁰ | Lucas Schilling^{46,56,61} |
 Allis F. Sellek⁶² | Ana Sosa⁶³ | Leonel T. Takada³⁶ | Antonio L. Teixeira^{64,65} |
 Martha Unaicho-Pilalumbo^{22,66} | Claudia Duran-Aniotz^{2,3} 

¹School, of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK²Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Santiago, Chile³Center for Social and Cognitive Neuroscience (CSCN), School of Psychology, Universidad Adolfo Ibanez, Santiago, Chile⁴Global Brain Health Institute, Trinity College, Dublin, Ireland⁵Memory and Neuropsychiatric Clinic (CMYN) Neurology Department, Hospital del Salvador y Facultad de Medicina, Universidad de Chile, Santiago, Chile⁶Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department – Institute of Biomedical Sciences (ICBM), Neuroscience and East Neuroscience Departments, Faculty of Medicine, Universidad de Chile, Santiago, Chile⁷Unit of Brain Health, Department of Neurology and Neurosurgery, Faculty of Medicine, Universidad de Chile, Santiago, Chile⁸Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile⁹Laboratory for Cognitive and Evolutionary Neuroscience (LaNCE), Department of Psychiatry, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile¹⁰Graduate School, Faculty of Medicine, Universidad Mayor, Chile – Centro de Apoyo Comunitario a Personas con Demencia Kintun, Santiago, Chile¹¹Centro Uruguayo de Imagenología Molecular (CUDIM) – Centro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay

Mario A. Parra, Paulina Orellana, Tomas Leon, and Victoria Cabello G. contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

- ¹²Department of Neurology and Psychiatry, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile
- ¹³Global Brain Health Institute and the Memory and Aging Center, Weill Institute for Neurosciences, Departments of Neurology and Radiology & Biomedical Imaging, University of California, San Francisco (UCSF), San Francisco, California, USA
- ¹⁴Cognitive Neuroscience Center (CNC), Universidad de San Andrés, & National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina
- ¹⁵Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
- ¹⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- ¹⁷Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
- ¹⁸UK Dementia Research Institute at UCL, London, UK
- ¹⁹Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China
- ²⁰Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands
- ²¹Department of Neurology, Memory and Aging Center, UCSF, San Francisco, California, USA
- ²²Atlantic Fellow for Equity in Brain Health at the Global Brain Health Institute (GBHI), University of California San Francisco, San Francisco, California, USA
- ²³HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA
- ²⁴Medical School, Aging Institute and Psychiatry Department, Neuroscience PhD Program, Pontificia Universidad Javeriana, Bogotá, Colombia
- ²⁵Memory and Cognition Center, Intellectus, Hospital Universitario San Ignacio, Bogotá, Colombia
- ²⁶Psychiatry Department, Hospital Universitario Santa Fe de Bogotá, Bogotá, Colombia
- ²⁷Universidad Nacional Pedro Henríquez Ureña (UNPHU), Santo Domingo, República Dominicana
- ²⁸Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Instituto Neurológico Fleni, Buenos Aires, Argentina
- ²⁹Department of Neurosciences, Universidad de la Costa, Barranquilla, Colombia
- ³⁰Faculty of Human Medicine, Postgraduate Section, National University of San Marcos, Lima, Perú
- ³¹Mental Health Service, Clínica Universidad de los Andes, Santiago, Chile
- ³²Department of Psychiatry, Medicine School, Andrés Bello University of Santiago (UNAB), Santiago, Chile
- ³³Center for Advanced Clinical Research (CICA), Department of Neurology & Neurosurgery and Neuroscience Department, Faculty of Medicine, Universidad de Chile, Santiago, Chile
- ³⁴Department of Neurology and Neurosurgery, Hospital Clínico Universidad de Chile, Santiago, Chile
- ³⁵Department of Neuroscience, Faculty of Medicine, Universidad de Chile, Santiago, Chile
- ³⁶Cognitive and Behavioral Neurology Unit, Department of Neurology, University of São Paulo Medical School, University of São Paulo, São Paulo, Brazil
- ³⁷Departamento e Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo HCFMUSP, São Paulo, Brazil
- ³⁸Behavioral and Cognitive Neurology Unit, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- ³⁹Instituto Nacional de Ciencias Neurológicas, Lima, Perú
- ⁴⁰Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay
- ⁴¹Unit of Diagnosis of Cognitive Impairment and Dementia Prevention, Instituto Peruano de Neurociencias, Lima, Perú
- ⁴²Department of Neuropsychology, Institut of Neurology, Hospital de Clínicas, Faculty of Medicine, Universidad de la República, Montevideo, Uruguay
- ⁴³Cognition and Brain Plasticity Unit, Bellvitge Biomedical Research Institute, Barcelona, Spain
- ⁴⁴Department of Cellular Biology, Physiology and Immunology, Neuroscience Institute, Autonomous University of Barcelona, Barcelona, Spain
- ⁴⁵Department of Internal Medicine, Health Sciences Faculty, Technical University of Ambato, Tungurahua, Ecuador
- ⁴⁶Neurology Service, School of Medicine, Pontifical University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
- ⁴⁷Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
- ⁴⁸School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru
- ⁴⁹Unit of Cognitive Diseases, Neuromedicenter, Quito, Ecuador
- ⁵⁰Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- ⁵¹Unit of Cognitive Evaluation, Department of Geriatrics and Gerontology, Hospital de Clínicas, Faculty of Medicine, Universidad de la República, Montevideo, Uruguay
- ⁵²Grupo de Neurociencias de Antioquia, Universidad de Antioquia, School of Medicine, Medellín, Colombia
- ⁵³Department of Geriatrics and Gerontology, Hospital Central de la Fuerza Aérea del Perú, Lima, Perú
- ⁵⁴Neurosciences Institute, Favalaro Foundation University Hospital, Buenos Aires, Argentina
- ⁵⁵Group of Neuropsychology and Behavior, Universidad de Antioquia, School of Medicine, Medellín, Colombia
- ⁵⁶Brain Institute of Rio Grande do Sul, Pontifical University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil
- ⁵⁷Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil

⁵⁸Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana Alzheimer's Disease Research Center, Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA

⁵⁹Research Group, MI Dneuropsy, Universidad Surcolombiana, Neiva, Colombia

⁶⁰Unit of Neuropsychogeriatry, Instituto Nacional de Geriatria, Santiago, Chile

⁶¹Graduate Program in Biomedical Gerontology, Pontifical University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil

⁶²FundAlzheimer, Memory Clinic, Cartago, Costa Rica

⁶³Instituto Nacional de Neurología y Neurocirugía (INNN), Manuel Velasco Suarez, Ciudad de México, México

⁶⁴Faculdade Santa Casa BH, Belo Horizonte, Brazil

⁶⁵Neuropsychiatry Program, University of Texas Health Science Center at Houston, Houston, Texas, USA

⁶⁶Departamento de Neurología, Hospital Universidad Técnica Particular de Loja, Loja, Ecuador

Correspondence

Claudia Duran-Aniotz, Latin American Brain Health Institute (BrainLat), Diagonal las Torres 2640, Peñalolén, Santiago, Chile.
Email: claudia.duran@uai.cl

Abstract

Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.

1 | INTRODUCTION

Dementia in Latin American and Caribbean (LAC) countries is a major public health challenge.¹⁻⁴ The prevalence of dementia in LAC countries among individuals 65+ years of age is higher than in Europe and the United States, ranging from 7.1% to 11.5%, and is expected to triple by 2050.⁵⁻⁷ It has been estimated that currently, >58% of all people living with dementia are in lower-middle income countries (LMIC) and that will increase to 68% in 2030.^{8,9} Importantly, most of the LAC countries are classified in the "upper-middle income group" (UMIC). Here, we report on the results from an online survey completed by dementia specialists from two higher income countries (HIC; Chile and Uruguay) and eight UMIC (Argentina, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, and Peru).¹⁰

1.1 | Dementia diagnosis harmonization in LAC: Challenges

The diagnosis of dementia has evolved from a purely clinical process to become a more complex exercise that integrates neuropsychological

and biomarker evidence.^{11,12} The former requires culturally adapted and validated instruments that are sensitive and specific to a wide range of age-related diseases that cause cognitive impairment. It also relies on clinically experienced examiners who are up to date in current challenges. The latter includes central (i.e., imaging) and peripheral methodologies, both heavily reliant on highly specialized personnel, expensive technologies, and sophisticated analytical tools.^{13,14}

1.2 | Biomarkers in dementia

Biomarkers are indicators that objectively measure and evaluate normal or pathological biological processes.¹⁵ Currently validated biomarkers in Alzheimer's disease (AD) are amyloid beta 42 (A β 42), total tau (t-tau), and phosphorylated tau (p-tau) proteins, which are measured in cerebrospinal fluid (CSF).¹⁶⁻²⁰ In addition, neuroimaging studies are also considered biomarkers validated for AD diagnosis, including magnetic resonance imaging (MRI), positron emission tomography (PET) with F18-fluorodeoxyglucose (FDG) and PET with the use of tracers for A β and tau in vivo.²¹⁻²⁸ Validated central biomarkers have been grouped into three categories: A/T/N, where A refers

to A β markers (PET A β or A β 42 in CSF); T to tau markers (p-tau in CSF or tau PET), and N to neurodegeneration markers (FDG-PET, MRI or t-tau in CSF).^{11,29} To date, CSF and neuroimaging biomarkers have proved of great utility. However, they are not easily accessible to patients. For this reason, multiple investigations have focused on the identification of biomarkers in peripheral fluids where it is possible to detect early pathological changes that occur in the brain during the development of dementia³⁰ thus proving promising for intervention strategies. Importantly, peripheral biomarkers have the potential to be accessible to people living far from capital cities where the infrastructure to perform central biomarker assessments is normally located. This entails a significant reduction of costs thus enhancing equity in dementia diagnosis. Peripheral biomarkers can be different molecules such as proteins, peptides, nucleic acids, microRNAs (miRNAs), lipids, and metabolites which can be detected in plasma, serum, exosomes or cellular components.³¹⁻³³ The investigation and development of peripheral biomarkers, specifically blood-based biomarkers for dementia, are in early stages. Ongoing efforts are focusing on their clinical evaluation and validation to explore opportunities for their future integration into clinical practice.³⁴ Because heritability rates for dementia range from 40% to 80%, other biomarkers commonly evaluated are genetic.³⁵ Some genes involved in dementia are: amyloid precursor protein (APP),³⁶ presenilin-1 (PSEN1),³⁷ presenilin-2 (PSEN2),³⁸ chromosome 9 open reading frame 72 (C9orf72),³⁹ granulin precursor (GRN),⁴⁰ and microtubule-associated protein tau (MAPT) genes,⁴¹ among other. In addition, some specific pathway genes have also been associated with increased risk, such as apolipoprotein E (APOE) ϵ 4.⁴²

1.3 | Biomarkers in LAC: the status quo

The biomarkers suggested by recent consensus^{11,29} are both scarce and scattered in LAC.^{43,44} Regarding PET scans, economic and political factors were identified as barriers to advances in PET imaging in LAC. Among others, the lack of infrastructure was highlighted (e.g., neighboring cyclotron).⁴⁵ Since these earlier reports, we have witnessed the emergence of multiple PET facilities in LAC (Instituto Neurologico Fleni in Buenos Aires, Argentina; University of São Paulo-USP and PUC-RS in Porto Alegre, Brazil; Centro Uruguayo de Imagenología Molecular CUDIM in Montevideo, Uruguay; and Instituto Nacional de Neurología y Neurocirugía [INNN] in Mexico City, Mexico).⁴⁶⁻⁵² Regarding CSF, sample collection is the main barrier identified in LAC. The invasiveness of this procedure poses significant limitations to its wide use and acceptance.⁴³ Nevertheless, a few examples are worth highlighting. Argentina and Brazil have conducted studies using CSF biomarkers. They have reported differences between controls, cognitively impaired patients, AD, and other types of dementia.^{46,53-57} In Colombia, CSF biomarkers were evaluated in young (40-50 years old) carriers of PSEN1 mutation and non-carriers, where clear differences in A β ₁₋₄₂ were identified between the two groups, which correlates with the clinical progression of this familial variant of AD.⁵⁸

RESEARCH IN CONTEXT

- 1. Review:** An online survey was created to identify the current use and accessibility of biomarkers for the diagnosis of dementias in Latin American and Caribbean (LAC) countries. This survey was answered by 48 participants from 10 LAC countries.
- 2. Interpretation:** The results provide information about a prominent potential in LAC to perform research on dementia biomarkers, as respondents of the survey showed high interest. The main barriers identified to using biomarkers correspond to funding, infrastructure, and lack of personnel training.
- 3. Future Directions:** A main action plan was suggested that addresses the recommendations for a biomarker framework recently proposed by LAC regional experts.

The above-mentioned examples are drawn from a limited set of labs and countries. Such labs are confined to centers specialized in dementia, such as memory clinics, where there is more experience in the diagnosis of dementia.⁵⁹ Additionally, LACs' native populations are characterized by a combination of demographic, ethnic, genetic, and socio-cultural factors that enable the investigation of biomarker profiles linked to dementia risk difficult to identify in other parts of the world. Given the ancestry and genetic admixture that characterize LAC^{1,2} such studies are of a great importance.

1.4 | Emerging biomarkers in LAC: opportunities

Because dementia has been declared a global challenge, the regional and international community must come together to devise and implement regional and global strategies. There are now a few recent examples from LAC that support the impact of joint efforts. The Latin America and the Caribbean Consortium on Dementia (LAC-CD) and The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat) are two prominent initiatives that have highlighted the need to harmonize practice across LAC and have proposed a new knowledge-to-action plan that includes a Biomarker Framework.^{3,44,60,61} Briefly, LAC-CD, at the time this survey study was run, involved 172 members from Central and South American countries with an interest and different levels of expertise in dementia research and clinical practice.⁶¹ They have been working collaboratively from 2015 to identify opportunities, formulate an integrated agenda, promote collaborative research and training, harmonize clinical practices, and raise awareness in dementia at all levels (<http://lac-cd.org/en/about-us/>). ReDLat, a research project involving 13 sites across Latin America and the United States, aims to expand open regional research by combining genomic, social determinants of health,

neuroimaging, and cognition in >4000 individuals to improve the characterization of AD and frontotemporal lobar degeneration (same ref as above). Recently, the Latin American Brain Health Institute (BrainLat) has been established as a result of a partnership between the University Adolfo Ibáñez of Chile and the Global Brain Health Institute (GBHI), which is an initiative of the University of California San Francisco (UCSF) and Trinity College Dublin (TCD; <https://brainlat.uai.cl/>). In Mexico, the National Dementia BioBank (BND) has been implemented.⁶² The readiness of LAC to embark on such plans has been acknowledged,⁴³ placing the region in a unique position to move toward more ambitious targets such as a harmonized and global biomarker framework.^{3,63}

An emergent area that holds significant potential for LAC is that of peripheral biomarkers,^{64–66} involving different molecules such as proteins (including plasma A β 42/A β 40, plasma p-tau, and plasma neurofilament, which cover the ATN framework for AD diagnostics in CSF, but also other proteins, for example, inflammation markers), peptides, nucleic acids, miRNAs,⁶⁶ lipids, and metabolites.⁶⁵ The advantage of peripheral biomarkers over CSF is the easy, less invasive, and inexpensive sample collection (plasma, serum, urine, among others).⁶⁷ Because biomarkers in peripheral fluids minimize risk and discomfort for patients, thus expanding their applicability in an aging population, large-scale peripheral fluid-based tests can become the primary tool and the first step in a dementia diagnostic process. They can become screening tools that can inform who should then undergo more expensive and invasive assessments, such as CSF biomarkers or neuroimaging.⁶⁸ A peripheral fluid-based test could also be useful for monitoring therapeutic outcomes, especially if repeated measurements are required over a short period of time as they may be more accessible in low-resource and non-specialized settings.^{69,70} In the future, these early detection biomarkers in peripheral fluids would also be useful in the development of clinical trials of new drugs, allowing a more accurate selection of individuals who meet the necessary criteria to participate in such trials.^{34,70–72}

Aware of the above challenges and opportunities, we decided to further investigate regional realities in LAC. We focused on central biomarkers such as CSF as well as neuroimaging, peripheral fluids, and genetics biomarkers. This study was not only aimed at providing an updated picture of the biomarker realities in LAC but also to assess the level of interest and readiness the region holds to embark on biomarker research. We envisaged that this knowledge would help expand opportunities in the region to make biomarker research more inclusive and representative, leveling the playfield, and in so doing enabling global biomarker agendas.

2 | METHODS

2.1 | Survey generation, distribution, and data capture

The survey was developed by a group of professionals with extensive experience in the areas of biomarkers, dementia, neurology, psychia-

try, and neuropsychology from LAC countries. Five meetings, involving multidisciplinary experts in the mentioned areas, were held to create the survey including the co-authors MAP, CDA, AD, AS, FH, PO, and VC. The survey gathered the largest amount of information regarding the status of central, peripheral biomarkers, and genetic studies for dementia in LAC countries considered to date. It requested information regarding accrued experience, barriers, and level of readiness of centers and labs in the region. Our main goal was to identify shared concerns and opportunities present in the region that can allow us to align our agenda both regionally and with international initiatives.

The survey was distributed among the 172 members of LAC-CD (<http://lac-cd.org/en/members/>) via e-mail. It was created as a Google Form and distributed in Spanish, Portuguese, and English. The survey body comprised 90 different questions grouped by biomarker type (see also Appendix S1 in supporting information) and it took approximately 20 minutes to complete. It was first sent on August 15, 2020, followed by two reminders (September 17, 2020 and March 7, 2021) with a total period of availability of 8 months.

The survey started with a brief introduction of its objective and a brief presentation of the group leading this initiative. It requested general information such as country, profession, and workplace. The questions in the survey were linked to the following biomarker classes: central biomarkers, which included CSF and neuroimaging modalities; peripheral biomarkers, which included fluids such as plasma, serum, whole blood, saliva, urine, deposition, ocular biomarkers, and others; and genetic studies, which presented a list of different genes related to dementia and their subtypes. A set of questions was asked for each biomarker class including current use, purpose, barriers, funding, motivation to work with biomarkers, and access to the population for research purposes. Questions were in the form of multiple-choice or open-ended (see Appendix S1). This study was approved by the Ethics Committee of the Universidad Adolfo Ibáñez, Chile.

2.2 | Data analysis

The data were exported as a Microsoft Excel file and answers in the three different languages were organized into one document. The multiple-choice questions were scored and then converted to percentages. The open-ended questions were qualitatively analyzed and grouped in relation to predefined criteria: access to study samples, published papers related to biomarkers in LAC, barriers, other types of funding, interest, and motivation (or lack of them) to work with specific biomarkers, among others. Empty, inconsistent, or incomplete data were discarded ($n = 2$). The figures were created by using GraphPad® Prism® 8.

3 | RESULTS

3.1 | Responses

The survey was answered by 48 participants (28% of LAC-CD members) from 10 countries in total (Figure 1). The countries with the




FIGURE 1 Distribution of survey responses from the 48 participants by country

highest participation were Brazil (27%), Peru (21%), and Chile (17%). Of the 48 participants, 27 were male and 21 female. Their professional specialties were general practitioners ($n = 3$), neurologists ($n = 26$), psychiatrists ($n = 8$), neurologist-psychiatrist ($n = 1$), geriatricians ($n = 3$), gastroenterologist ($n = 1$), physician-neuropsychologist ($n = 1$), neuropsychologists ($n = 2$), and researchers ($n = 3$). They reported to be associated to 37 public institutions, nine private institutions and two public-private institutions, indicating that the majority of the participants (81%) worked in public institutions.

3.2 | Biomarkers used, purposes, and funding

In this section, we summarize the answers of the respondents related to biomarkers use and interest, purpose, and funding.

3.2.1 | Biomarkers use and interest

We divided the 48 respondents into those who are currently using biomarkers and those who are not using them, but are interested/uninterested in their future use. Neuroimaging is the biomarker that is currently most widely used, as reported by 35 respondents (73%), with 12 of the remaining respondents (25%) reporting they would be interested in using them and only one respondent (2%) reporting no interest in using this biomarker. On the other hand, CSF biomarkers are the least currently used with only 14 respondents reporting their use (29%). However, 22 respondents (46%) are interested in using them if available. There were 12 (25%) respondents who are uninterested in using this type of biomarker. Despite their novelty, peripheral fluid biomarkers are being used by 15 respondents (31%), and 26 (54%) reported an interest in their future use. Only seven respondents (15%) are not interested in this type of biomarker. Finally, genetic biomarkers attracted a similar number of responses regarding use (19, 40%) and interest (20, 41%), with nine respondents (19%) reporting no interest in their use (Figure 2A).

3.2.2 | Biomarker purposes

In the field of neuroimaging, from the 35 participants currently performing studies, half of them reported using these biomarkers for

both clinical and research purposes (17 respondents, 49%), whereas their use in either clinical practice or research practice shared a similar trend, 8 (23%) and 10 respondents (29%), respectively. From the 12 respondents interested in future use of neuroimaging, 11 (92%) would like to perform neuroimaging for clinical and research purposes whereas only one respondent (8%) would like to use it only for research. In terms of CSF biomarkers, of the 14 respondents currently using them, 7 (50%) use them for research, 5 (36%) for clinical and research, and 2 respondents (14%) for only clinical purposes. Of the 22 participants interested in using CSF biomarkers in the future, 15 of them would like to use them for clinical and research purposes (67%) and 7 (33%) only for research. Regarding peripheral biomarkers, of the 15 respondents currently using them, 14 respondents are using them for research (93%) whereas only 1 respondent (7%) is using them for research and clinical purposes. Of the 26 respondents who are interested in using them in the future, 16 respondents would use them for research and clinical purposes (62%) and 10 only for research (38%). Finally, for genetic studies, of the 19 respondents interested in performing them, 13 respondents would use them for research (68%) whereas 6 (32%) would use them for clinical and research purposes. The participants who are not currently using biomarkers, 20 respondents, reported the purposes for which they would like to use them in the future: 15 respondents indicated interest in using them for research and clinical purposes (75%), 4 respondents for research only (20%), and 1 for clinical practice (5%; Figure 2B).

3.2.3 | Funding for biomarkers

Regarding funding opportunities to support the use of biomarkers, the respondents, using or interested, reported the funding type for each one of these biomarkers (neuroimaging, CSF, peripheral and genetic studies). The sum of answers of the respondents that currently work with biomarkers stated that most of their funding opportunities came from public grants (51%) followed by no funding (18%), private funds (13%), a mix between public and private funds (13%), and "other type of funding resources" (5%). However, this trend changes for the respondents that are interested in using biomarkers as a high number of respondents state a lack of funding opportunities (64%), followed by public grants (16%), "other type of funds" (9%), a mix of public and private funds (6%), and private funds (5%; Figure 2C).

3.3 | Biomarker-specific characterization in LAC

In this section, we summarize the answers of the respondents related to the specific subtypes of biomarkers they are using or interested in using (Figure 3).

3.3.1 | Neuroimaging

For neuroimaging biomarkers, 95 responses were recorded considering seven options of a multiple-choice question. The modality of neuroimaging most commonly used corresponds to MRI (33 answers,




FIGURE 2 Biomarkers used, purposes, and funding. A, Using, interested, and uninterested respondents by type of biomarker. B, Purpose of the use of biomarkers in LAC. C, Funding sources for biomarker studies in LAC. CSF, cerebrospinal fluid; LAC, Latin American and Caribbean

35%), followed by FDG-PET (16 answers, 17%), diffusion tensor imaging (DTI; 13 answers, 14%), amyloid PET (11 answers, 12%), functional MRI (fMRI; 13 answers, 14%), and tau PET (4 answers, 4%; Figure 3A). Concerning other types of neuroimaging methods, 5 (5%) use techniques such as single-photon emission positron tomography (SPECT), 18 F-fluoro-L-DOPA positron emission tomography (PET-DOPA), and brain tomography. The neuroimaging equipment most used is 1.5 and 3.0 Tesla with a clinical objective of patient evaluation and longitudinal follow-up. In addition, the most used MRI techniques for structural analysis in research are cortical thickness and voxel-based morphometry (VBM), whereas the most used for functional analysis is the resting-state fMRI. Of the 44 respondents not using neuroimaging biomarkers but interested in their future use, 9 (20%) expressed an interest in MRI, 9 (20%) in tau PET, 8 (18%) in fMRI, 8 (18%) in FDG-PET, 8 (18%) shared a similar interest in these specimens but amyloid PET, 1 (2%) in DTI, and 1 (2%) in other not listed in the survey (Figure 3A).

3.3.2 | CSF biomarkers

For CSF biomarkers, a total of 43 responses were gathered reflecting their use by 13 (30%) for A β , 13 (30%) for t-tau, 13 (30%) for

p-tau, and only 4 (10%) search for other types of CSF biomarkers such as neurofilaments, neurotransmitters, inflammatory markers, and hormones. Interested respondents ($n = 61$), indicated their motivation for A β (19, 31%), t-tau (20, 33%), p-tau (18, 29%), and other (4, 7%) such as neurofilaments, microRNAs, neurogranin, and prion protein detection (Figure 3B). In addition, the most used technique to analyze biomarkers in CSF is enzyme-linked immunosorbent assay (ELISA) and the techniques that would be chosen for CSF biomarkers analysis are single molecule array (SIMOA) and ELISA.

3.3.3 | Peripheral biomarkers

Regarding the main peripheral fluids, we obtained 34 responses, which showed a high tendency toward the study of blood samples and their components (83%) distributed as: 14 (41%) plasma, 7 (21%) serum, 7 (21%) whole blood. Other fluids used with less frequency correspond to 3 (9%) saliva, 1 (3%) deposition, 1 (3%) ocular biomarker, and other 1 (3%) like platelets. The number of interested respondents was similar to that using them, with 30 responses distributed as: 8 (27%) plasma, 6 (20%) serum, 5 (17%) whole blood, 5 (17%) saliva, 3 (10%) urine, 2 (7%) ocular biomarkers, and 1 (3%) deposition (Figure 3C). Concerning the type of peripheral biomarkers in current use, we found a wide




FIGURE 3 Biomarker characterization in LAC. A, Neuroimaging. B, CSF biomarkers. C, Peripheral fluids. D, Genetic biomarkers. CSF, cerebrospinal fluid; DTI, diffusion tensor imaging; FDG, fluorodeoxyglucose; fMRI, functional magnetic resonance imaging; GWAS, genome-wide association studies; MRI, magnetic resonance imaging; LAC, Latin American and Caribbean; PET, positron emission tomography

variety: neurodegeneration markers ($A\beta$, tau, p-tau, neurofilaments), inflammatory markers (i.e., cytokines, lactoferrin, lipoxin, annexin), hormones (cortisol, metabolomics), hemostatic markers, and miRNAs. Furthermore, regarding the percentage of the peripheral biomarkers they would be interested in using, most respondents mentioned neurodegeneration markers such as 35% $A\beta$, 35% t-tau, 10% p-tau, 8% neurofilaments, 2% TDP-43, and 2% neurogranin. Interestingly, 6% of responders stated they would be interested in using “all biomarkers that I could work with.” The currently used techniques to study peripheral biomarkers are ELISA, cytometric bead array (CBA), Multiplex Luminex, and SIMOA, and the techniques respondents prefer to use are ELISA and SIMOA.

3.3.4 | Genetic studies

From the multiple-choice question 82 responses were obtained, reporting that the main genes assessed in genetic studies are: 16 (20%) *APOE*, 9 (11%) *MAPT*, 9 (11%) *PSEN1*, 8 (10%) *PSEN2*, 8 (10%) *APP*, 7 (9%) *C9orf72*, 7 (9%) *PGRN*, 5 (6%) *TREM2*, 6 (7%) *TARDBP*; 3 (4%) perform genome-wide association study (GWAS); analysis and 4 (5%) studied other genes such as *PRNP*, vitamin D receptor polymor-

phism, exome, Huntington's, and Parkinson's populations. Additionally, regarding the genes that respondents are interested in using for genetic studies, the following trend can be observed from 96 answers: 18 (19%) *APOE*, 14 (15%) *PSEN1*, 13 (14%) *PSEN2*, 12 (13%) *APP*, 9 (9%) *MAPT*, 8 (8%) *C9orf72*, 8 (8%) *PGRN*, 6 (6%) *TARDBP*, 4 (4%) *TREM2*, and 4 (4%) *GWAS* (Figure 3D). The principal techniques to perform genetic studies currently used and of interest are real-time polymerase chain reaction (PCR), used to detect specific polymorphisms or mutations, Sanger sequencing, and next generation sequencing (NGS).

3.4 | Experience to date

One of the main questions regarding the use of biomarkers was related to the number of years that clinicians and researchers from the different LAC countries have been using the different types of biomarkers. Brazil was the country with the most years per respondent working in neuroimaging, followed by Ecuador, Uruguay, Peru, and Chile. We found the same pattern for CSF biomarkers, whereby Brazil, followed by Peru, shows prominent results with more years of experience than other countries. In peripheral biomarkers, which is the newest field of study, Brazil leads the results of years of experience in these techniques




FIGURE 4 Years of experience in the use of biomarkers of respondents by country and per biomarkers. CSF, cerebrospinal fluid

followed by Chile. Finally, in genetics studies, Colombia was at the top followed by Brazil with prominent years of experience and close to Chile (Figure 4).

3.5 | Access to unique populations in LAC

Regarding neuroimaging, Argentinians reported having access to populations with familial AD and Down's syndrome, whereas Brazilian respondents reported having access to different populations with diagnoses of cognitive impairment and dementia, specifically White, Black, and admixed populations. Chilean respondents reported having access to dementia and Parkinson's disease (PD) populations, and Colombian respondents indicated access to populations with genetic AD, frontotemporal dementia (FTD), PD, Huntington's disease, and vascular hereditary dementia CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) type. Costa Rican respondents reported having access to mixed populations; Dominican respondents reported having access to the general population; and Ecuadorian respondents reported having access to cognitive impairment, dementia, and ethnic populations. Finally, Peruvian respondents indicated access to the general population, illiterate adults, and to ethnic groups such as the Quechua and Aymara.

Regarding the possibility of performing neuroimaging studies with such populations in LAC, 60.5% of the respondents confirmed that this option is available whereas 39.5% responded that this is not available for them. Regarding CSF biomarkers in LAC, in Argentina, respondents reported having access to samples of Down's syndrome. Brazil indicated access to samples from different ethnic groups like White, Black, and admixed samples. Colombia reported access to CSF samples in families with autosomal dominant AD, FTD, and vascular hereditary dementia CADASIL type, whereas Ecuador has access to samples of the indigenous population.

Regarding the possibility of performing CSF studies in such populations, 57.4% of the respondents confirmed they would be able to access them for research purposes. Regarding biofluids, Brazil has access to peripheral samples from different ethnic groups such as White, Black, and admixed individuals. In Chile, there is access to samples of elderly

members of the Geroscience Center for Brain Health and Metabolism (GERO) cohort.⁷³ In Colombia, there is access to samples of families with autosomal dominant AD and vascular hereditary dementia CADASIL type. With respect to the possibility of performing peripheral fluid biomarkers studies in different populations in the future, 71.7% of the respondents of the survey answered that they would be able to access them while 28.3% would not.

Regarding genetic studies, Argentina indicated that the genetic samples obtained come from family forms of different dementia populations, including Down syndrome. In Brazil access to samples from Afro-Brazilian and Asian-Brazilian people is available. In Chile, a regional cohort study of aged individuals (GERO) is currently collecting samples.⁷³ Colombia has the widest access via their genetic clusters including AD, FTD, PD, Huntington disease and vascular hereditary dementia CADASIL type. Peru will now start collecting genetic samples from patients with mild cognitive impairment (MCI) and mild AD in Quechua and Aymara populations. In relation to the possible access to genetic samples to perform future studies, 59% of respondents of the survey could have access to genetic samples from different populations in their country. In contrast, 41% of the respondents indicate that obtaining samples from a diverse population is not possible.

3.6 | Barriers to the use of biomarker

3.6.1 | Barriers to perform biomarkers studies in LAC

The identified barriers from this survey were: funding, infrastructure, and knowledge (as technical personnel and human resources). The main barrier to the use of the analyzed biomarkers is the lack of funding to perform clinical and research studies, whereas the second leading barrier identified was the infrastructure. Of the total of responses from respondents currently using or interested in using neuroimaging, CSF, peripheral fluid, and genetic studies, $\approx 73\%$ of the former and 60% of the latter group reported that funding is a main barrier. The second more prominent barrier was knowledge, reporting 16% of the answers of the respondents currently using these biomarkers and 19% of the answers of the respondents interested. Regarding infrastructure as a barrier, 11% of the answers corresponded to respondents using these biomarkers and 21% of to those interested (Figure 5A).

3.6.2 | Attitudes toward dementia biomarkers in LAC

Finally, in the survey we asked the respondents the reasons why they are not working with biomarkers, or why they are not interested in using them. Respondents not working (45%) or uninterested (39%) in using neuroimaging, CSF, peripheral fluid, and genetic biomarkers reported that lack of funding was the main barrier. The second barrier was the infrastructure, reported by 31% of the respondents currently not using biomarkers and 28% of those uninterested. With




FIGURE 5 Barriers to perform biomarkers studies in LAC. A, Barriers to perform biomarkers studies. B, Possible barriers to perform biomarkers studies for uninterested respondents. CSF, cerebrospinal fluid; LAC, Latin American and Caribbean

TABLE 1 Publications of Latin American respondents

Country	Biomarker	Mean impact factor	Number of papers
Argentina	9(1) P(2) 3(3) P(3) ∞(1) Q(3)	4.805	13
Brazil	9(26) P(7) A(22) 3(8) f(2) ∞(1) O(5) p(1)	3.749	72
Chile	9(2) A(3) 3(1) f(1)	3.996	7
Colombia	3(11) ∞(11) P(1) O(1) A(1) A(3)	14.962	28
Mexico	A(4) 3(3) ∞(2) 9(2)	3.575	11
Peru	3(1)	4.347	1
Uruguay	9(1)	3.552	1

Note: 9, neuroimaging; P, CSF; A, peripheral fluid; 3, genetic; P, neuroimaging and CSF; f, neuroimaging and peripheral fluid; ∞, neuroimaging and genetic; Q, neuroimaging, CSF, and genetic; Y, neuroimaging, peripheral fluid, and genetic; O, peripheral fluid and genetic; p, CSF and genetics; A, neuroimaging, CSF, and peripheral fluids; A, neuroimaging, CSF, peripheral fluids and genetics. Abbreviation: CSF, cerebrospinal fluid.

regard to knowledge as a barrier, 14% of the answers corresponded to the participants not using these biomarkers and 17% to those uninterested. Among the options in the survey regarding possible reasons for not being interested in performing biomarker studies, only four respondents reported they consider these are “not necessary” or “unreliable.”

3.7 | Publications of Latin American respondents

The respondents of the survey reported published papers about biomarker studies developed in LAC populations from Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Uruguay. Brazil reported 72 publications, most of them related to neuroimaging and peripheral fluids, followed by Colombia reporting 29 publications related to genetics studies published in high impact factor journals. On the other hand, Peru and Uruguay reported only one publication each (Table 1).

4 | DISCUSSION AND CONCLUSION

Limited knowledge and implementation barriers for dementia biomarkers in LAC countries remain serious challenges. The main motivation of this survey was to collect updated information to provide a representative and inclusive overview of the reality and implications of the use of the different types of biomarkers in LAC.

4.1 | Biomarkers use and interest

Neuroimaging is the most widely used biomarker by the respondents of our survey. Neuroimaging biomarkers that hold well-known clinical value, such as MRI and FDG-PET, are the most frequently used whereas the others (DTI, PET, fMRI, SPECT) are used though to a smaller extent and are more scattered among LAC countries. It is worth noting that genetic biomarkers were the second class most frequently used after

neuroimaging. A reason for this may be due to the presence of genetic clusters of mutations linked to dementia subtypes that have been and continue to be identified in the region.⁷⁴

It is also important to emphasize that respondents have identified peripheral biomarkers as the class that they are most interested to use in the future, followed by CSF and genetic studies. This coincides with the increasing use of CSF and peripheral biomarkers in various centers in LAC.

4.2 | Biomarker purposes

Relative to other biomarkers classes, neuroimaging seems to be the method most widely used in clinical practice. Even respondents who do not use it are interested and see this as a useful tool supporting clinical and research settings. This result may be explained by the growing body of evidence supporting the use of neuroimaging biomarkers throughout the dementia continuum (MCI⁷⁵) and care pathway including diagnosis,⁷⁶ progression,⁷⁷ and predicting treatment response.⁷⁸

Neither peripheral nor genetic biomarkers are currently reported as being used for clinical purposes. A barrier to the clinical implementation of peripheral biomarkers might be the lack of adequate centers and standardized protocols for sample processing. The application of a peripheral biomarker in clinical practice requires significant research and validation⁷⁹ as well as a continuous evaluation process.

4.3 | Barriers to biomarker use in LAC

Barriers to the implementation of biomarkers have been previously described.^{3,80} Importantly, the respondents of our survey provided crucial information related to the main barriers that they have been or they would be presented with to perform studies with biomarkers in LAC (Figure 5A). The main challenges and barriers reported in this study were funding, technical personnel, and infrastructure. However, those barriers were not equally distributed across LAC, with some countries such as Brazil or Argentina with strong research on biomarkers while others, including Costa Rica or Uruguay, have little to no research in the clinical use of biomarkers. In this context, the most accessible and cost-effective biomarkers, such as fluid biomarkers, represent a good opportunity to enhance diagnosis and dementia research in the region.

4.4 | Funding for biomarkers

Our study has identified that funding represents one of the main challenges in the implementation and use of biomarkers. Funding is limited and mainly granted by public agencies. It should be noted that even most of the respondents working in private centers have mainly public funding to carry out their research. Interestingly, biomarkers, which are being used mainly for research purposes (CSF, peripheral, and genetic),

are those attracting most funding in LAC (Figure 2B,C). It is worth noting that these are mainly located in advanced centers where the expertise is hosted. This indicates a centralization of knowledge and technological resources within each country and across the region. Nevertheless, it indicates a promising landscape for international collaborations and funding that would allow LAC to continue developing hubs for biomarker research, validation, and training.

Respondents with an interest in biomarkers who are currently not incorporating them in their practice have reported the lack of funding as one of their limitations. It will be worth exploring where these barriers lie as overcoming them would provide opportunities to set up facilities and increase the number of qualified professionals across the region. Improving grant proposals via strong regional and international collaborations would be a key strategy to fill these gaps. This survey provides key evidence that can inform such joint efforts. Furthermore, support is also needed to enhance capacity-building strategies via training programs offered by countries with strong infrastructure (i.e., biomarker hubs).

4.5 | Experience

As previously discussed by Parra et al.,² experience in the use of biomarkers is concentrated in a few LAC countries. Such experiences often map onto the population these countries have access to. For instance, Colombia reported experience in genetic biomarkers and access to large genetic clusters of families carrying rare single-gene mutations for various types of dementia (Table 1). On the other hand, countries such as Brazil, Argentina, Ecuador, Uruguay, Peru, and Chile have a long-standing experience in the use of biomarkers with heterogeneous populations (Table 1). We envisage that these countries can become hubs for biomarker research and training in LAC, which could lead to partnerships across countries for data exchange and cooperative research.

4.6 | Infrastructure

In our study, several respondents reported the lack of state-of-the-art laboratories to perform biofluid or genetic biomarkers analysis as a limitation, which is seemingly linked to the limited funding opportunities of the region. This pattern seems to be shared across respondents who are currently using and not using biomarkers. Moreover, it was reported that multiple research groups currently working on biomarkers have the need to outsource the genetic analysis of their samples to foreign laboratories, which may increase the cost of the use of biomarkers in research and clinical settings.

On another point, state-of-the-art neuroimaging equipment is available in highly specialized health institutions, most of them localized in capital cities, limiting the access to the general population. Less specialized health institutions that can be found in peripheral centers are regularly equipped with low- to middle-resolution scanners.

4.7 | Strengths and limitations of this study

LAC-CD is the most extensive regional network focused on neurodegenerative diseases. Although we tried to be as inclusive as possible by involving its entire membership, this attempt certainly yielded a biased sample. Nevertheless, this caveat seems to characterize different works led by a consortium and is one widely seen in the relevant literature. A significant number of members from LAC-CD are currently undertaking or have previously undertaken biomarkers research, and many of them work as both clinicians and researchers. Given the diversity, expertise, and representativeness of LAC-CD members that contributed to this survey, we feel confident to uphold the validity of the results reported here.

Another important limitation is that it was not possible to compare public and private centers. Only 11 respondents out of the total 48 (23%) are working in private centers. This small proportion did not allow us to perform further analysis to unveil differences across sectors. For instance, only two respondents linked to private centers are currently working with CSF biomarkers instead of 14 respondents belonging to public centers.

4.8 | Why is it important to review the status quo in LAC?

In the past few years, significant efforts have led to the creation of several Latin American networks aimed at promoting clinical and research activities on dementia.⁶⁰ One of the main challenges has been to harmonize procedures, ensuring that evidence-based protocols are available to LAC countries.^{2,3} To tackle the local challenges regarding dementia research, multinational networks aimed at identifying the unique genetic, social, and economic factors driving the presentation of FTD and AD have been set up.⁶¹ Regarding biomarkers, LAC research has focused on developing multicentric studies that integrate several biomarkers to provide a better classification of neurodegenerative diseases, evaluating the multi-dimensional data using artificial intelligence (AI) approaches such as machine learning.⁸¹ The LAC-CD Biomarker Framework aims to support the use, development, and validation of affordable biomarkers in the region with a special emphasis on peripheral biomarkers. Considering the role that some countries in the region are playing in the validation of the A/T/N biomarker framework, development of new drugs for the secondary prevention of AD together with the distinctiveness of risk and protective factors for dementia found in the region, we feel compelled to further encourage the implementation of the LAC-CD Biomarker Framework. This study provides the knowledge base that will inform the implementation of such a framework and ensuing initiatives.

4.9 | Biomarker opportunities in LAC

The impact of genetic ancestry and admixture on dementia prevalence and phenotypes in LAC has been widely acknowledged. LAC countries

are highly diverse, so investigating these factors will provide unique insights to better understand the interplay of social determinants of health, demographic variables, biomarkers of neurodegenerative pathologies, and risk of dementia. Regarding genetic features of LAC populations, we have highlighted the opportunities that such populations host for the advancement of biomarker research and drug development programs positioning LAC as a key example (Neuroscience Group of Antioquia, Instituto Neurológico FLENI, ReDLat, PISA at University of Sao Paulo).

One key barrier extensively acknowledged in scientific literature is the lack of publications of LAC studies in high impact journals. However, this trend is rapidly changing with emerging networking initiatives.^{2,3,60} As the results from our survey, we have identified countries currently making significant contributions to knowledge building (Table 1) are those where biomarker expertise and resources are mostly gathered. We have suggested that these realities can change if such centers act as hubs to support capacity building and collaboration in the region and beyond. This situation also poses a great opportunity to form partnerships and create the space needed for knowledge exchange and capacity building in the LAC region.

5 | FINAL REMARKS

LAC hosts unprecedented opportunities to advance biomarker development and validation globally. Our survey suggests that the region holds positive attitudes to embark on such developments. Respondents of this survey who are not currently using biomarkers reported their eagerness to incorporate “all biomarkers that they could work with.” Previous reports have characterized regional realities and provided action plans to tackle them. Here, we specifically aim to contribute to the biomarker framework proposed by the LAC-CD's Knowledge to Action Plan, which includes: (1) Validation and implementation of harmonized protocols such as the A/T/N framework in LAC hubs. This survey provided evidence of centers that act as such hubs. (2) Strengthening of partnership with the Alzheimer's Association and the National Institutes of Health/National Institute on Aging (NIH/NIA) to improve regional grant proposals, expand funding opportunities and increase collaborative work among LAC-CD members. This survey has contributed evidence on funding barriers and eagerness of respondents to engage in collaborative work. We have initiated discussions with leaders of the Neuroimaging and Biofluid Based Biomarkers Professional Interest Areas of ISTAART to set up regional biomarker networks and collaborative groups. (3) Introduction of complementary affordable biomarkers based on new assessments depending on the infrastructure available in each LAC country included in this study. The survey contributed evidence on laboratories where biofluid-based biomarkers could be swiftly introduced or enhanced. We will invite these center and groups to join the LAC Biomarker Network to expand funding opportunities. (4) Improved understanding of the interplay of the genetic mechanisms, clinical phenotypes, and severity of neurodegenerative diseases. The survey provided valuable information that

complements previous efforts from LAC-CD³ and together they pave the way for future work on the above factors. There are ongoing initiatives that will contribute and further benefit from such work (ReDLat, NIH-R01 consortia grants of biomarkers/epigenetics/linguistic, and LAC funding of new peripheral biomarkers). (5) Promotion of efforts via capacity building, implementation science, and translational research to support regional dementia plans; enhance the regional health systems' infrastructure related to brain health; and facilitate future agreements with governments to increase the budget for dementia prevention, care, and research. We are confident that new collaborative initiatives currently considering the LAC region will soon materialize.

ACKNOWLEDGMENTS

We thank Sandro Casavilca-Zambrano, Gabriel Espinoza Coronel, Jose Carlos Huilca Flores, Pablo Martinez-Lage, Dongjun Yoo, and Fernando Lara Roquette, who participated in answering the survey. C.D.A. is partially supported by 2018-AARG-591107, ANID/FONDEF IDEA ID20I10152, ANID/FONDECYT Regular 1210622, and ANID/PIA/ANILLOS ACT210096. A.I. is supported by grants from CONICET; ANID/FONDECYT Regular (1210195 and 1210176); ANID/FONDAP (15150012); FONCYT-PICT 2017-1820; Takeda CW2680521; Sistema General de Regalías (BPIN2018000100059), Universidad del Valle (CI 5316); Alzheimer's Association GBHI ALZ UK-20-639295; and the MULTI-PARTNER CONSORTIUM TO EXPAND DEMENTIA RESEARCH IN LATIN AMERICA (ReDLat, supported by National Institutes of Health, National Institutes of Aging [R01 AG057234], Alzheimer's Association [SG-20-725707], Rainwater Charitable foundation-Tau Consortium, and Global Brain Health Institute). M.I.B. is supported by ANID/Fondecyt Regular (1190958), ANID/FONDEF-IDEA (ID20I10252 and ID19I10302), and ANID/Fondequip 2021. The contents of this publication are solely the responsibility of the authors and do not represent the official views of these Institutions. L.C.S. and P.C. hold a senior researcher grant (bolsa de produtividade em pesquisa) from CNPq, Brazil. STF is funded by the Brazilian agencies Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), and National Institute for Translational Neuroscience. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), European Union Joint Program for Neurodegenerative Disorders (JPND2021-00694), and the UK Dementia Research Institute at UCL. F.H. was supported by grants from ANID-Subdirección de Capital Humano/Doctorado Nacional/2021- 21211349, Chile.

CONFLICTS OF INTEREST

H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Author disclosures are available in the supporting information.

ORCID

Claudia Duran-Aniotz  <https://orcid.org/0000-0003-2503-8366>

REFERENCES

- Baez S, Ibanez A. Dementia in Latin America: an Emergent Silent Tsunami. *Front Aging Neurosci.* 2016;8:253.
- Parra MA, Baez S, Allegri R, et al. Dementia in Latin America: assessing the present and envisioning the future. *Neurology.* 2018;90:222-231.
- Parra MA, Baez S, Sedeno L, et al. Dementia in Latin America: paving the way toward a regional action plan. *Alzheimers Dement.* 2021;17:295-313.
- Nitrini R, Barbosa MT, Dozzi Brucki SM, Yassuda MS, Caramelli P. Current trends and challenges on dementia management and research in Latin America. *J Glob Health.* 2020;10:010362.
- Manes F. The huge burden of dementia in Latin America. *Lancet Neurol.* 2016;15:29.
- Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement.* 2013;9:63-75.e2.
- Nitrini R, Bottino CM, Alcala C, et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. *Int Psychogeriatr.* 2009;21:622-630.
- Wolters FJ, Chibnik LB, Waziry R, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States: the Alzheimer Cohorts Consortium. *Neurology.* 2020;95:e519-e531.
- Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World alzheimer report 2015 – The global impact of dementia: an analysis of prevalence, incidence, costs and trends. London: Alzheimer's Disease International, 2015. 84 p.
- World Bank. List of economies. June 2020. [https://www.hupo.org/resources/Documents/HPP/World%20Bank%20list%20of%20economies%20\(June%202020\).pdf](https://www.hupo.org/resources/Documents/HPP/World%20Bank%20list%20of%20economies%20(June%202020).pdf)
- Jack CR, Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14:535-562.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011;7:280-292.
- Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol.* 2007;6:734-746.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology.* 1984;34:939-944.
- El Kadmiri N, Said N, Slassi I, El Moutawakil B, Nadifi S. Biomarkers for Alzheimer disease: classical and novel candidates' review. *Neuroscience.* 2018;370:181-190.

16. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. *Lancet Neurol.* 2003;2:605-613.
17. Burger nee Buch K, Padberg F, Nolde T, et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. *Neurosci Lett.* 1999;277:21-24.
18. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. *Arch Gen Psychiatry.* 2004;61:95-102.
19. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. *Alzheimers Dement.* 2008;4:38-48.
20. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA.* 2009;302:385-393.
21. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. *Neuroscience.* 2000;95:721-725.
22. Zarow C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. *Ann Neurol.* 2005;57:896-903.
23. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. *JAMA.* 2001;286:2120-2127.
24. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). *Proc Natl Acad Sci U S A.* 2001;98:10966-10971.
25. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. *Eur J Nucl Med Mol Imaging.* 2003;30:1104-1113.
26. Koychev I, Gunn RN, Firouzi A, et al. PET tau and amyloid-beta burden in mild Alzheimer's disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. *J Alzheimers Dis.* 2017;60:283-293.
27. Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. *Neurology.* 2019;92:e601-e612.
28. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology.* 2018;91:e859-e866.
29. Jack CR, Jr, Bennett DA, Blennow K, et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology.* 2016;87:539-547.
30. Irizarry MC. Biomarkers of Alzheimer disease in plasma. *NeuroRx.* 2004;1:226-234.
31. Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. *Biomark Med.* 2010;4:65-79.
32. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. *Prog Neurobiol.* 2013;101-102:1-17.
33. Zetterberg H, Schott JM. Blood biomarkers for Alzheimer's disease and related disorders. *Acta Neurol Scand.* 2022;146(1):51-55.
34. Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. *Mol Neurodegener.* 2021;16:10.
35. van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. *J Neurol Neurosurg Psychiatry.* 2005;76(Suppl 5):v2-7.
36. Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer's disease. *J Alzheimers Dis.* 2006;9:341-347.
37. Cruts M, Hendriks L, Van Broeckhoven C. The presenilin genes: a new gene family involved in Alzheimer disease pathology. *Hum Mol Genet.* 1996;5 Spec No: 1449-55.
38. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science.* 1995;269:973-977.
39. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron.* 2011;72:245-256.
40. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature.* 2006;442:916-919.
41. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. *Ann Neurol.* 1998;43:815-825.
42. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology.* 1993;43:1467-1472.
43. Duran-Aniotz C, Orellana P, Leon Rodriguez T, et al. Systematic review: genetic, neuroimaging, and fluids biomarkers for frontotemporal dementia across Latin America countries. *Front Neurol.* 2021;12:663407.
44. Sexton C, Snyder HM, Chandrasekaran L, Worley S, Carrillo MC. Expanding representation of low and middle income countries in global dementia research: commentary from the Alzheimer's Association. *Front Neurol.* 2021;12:633777.
45. Tutor CA, Frias L. Development of PET in Latin America Experience of the first PET-Cyclotron Center. *World J Nucl Med.* 2002;1:219.
46. Allegri RF, Chrem Mendez P, Calandri I, et al. Prognostic value of ATN Alzheimer biomarkers: 60-month follow-up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. *Alzheimers Dement (Amst).* 2020;12:e12026.
47. Allegri RF, Chrem Mendez P, Russo MJ, et al. Biomarkers of Alzheimer's disease in mild cognitive impairment: experience in a memory clinic from Latin America. *Neurologia (Engl Ed).* 2021;36:201-208.
48. Cecchini MA, Yassuda MS, Squarzoni P, et al. Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. *Brain Cogn.* 2021;152:105749.
49. Damian A, Portugal F, Niell N, et al. Clinical impact of PET with (18)F-FDG and (11)C-PIB in patients with dementia in a developing country. *Front Neurol.* 2021;12:630958.
50. Faria DP, Duran FL, Squarzoni P, et al. Topography of 11C-Pittsburgh compound B uptake in Alzheimer's disease: a voxel-based investigation of cortical and white matter regions. *Braz J Psychiatry.* 2019;41:101-111.
51. Coutinho AM, Busatto GF, de Gobbi Porto FH, et al. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. *Eur J Nucl Med Mol Imaging.* 2020;47:2666-2680.
52. de Souza GS, Andrade MA, Borelli WV, et al. Amyloid-beta PET classification on cognitive aging stages using the centiloid scale. *Mol Imaging Biol.* 2022;24:394-403.
53. Hansen EO, Dias NS, Burgos ICB, et al. Millipore xMap(R) Luminex (HATMAG-68K): an accurate and cost-effective method for evaluating Alzheimer's biomarkers in cerebrospinal fluid. *Front Psychiatry.* 2021;12:716686.
54. Madeira C, Lourenco MV, Vargas-Lopes C, et al. d-serine levels in Alzheimer's disease: implications for novel biomarker development. *Transl Psychiatry.* 2015;5:e561.
55. Lourenco MV, Ribeiro FC, Sudo FK, et al. Cerebrospinal fluid irisin correlates with amyloid-beta, BDNF, and cognition in Alzheimer's disease. *Alzheimers Dement (Amst).* 2020;12:e12034.

56. Lourenco MV, Ribeiro FC, Santos LE, et al. Cerebrospinal fluid neurotransmitters, cytokines, and chemokines in Alzheimer's and lewy body diseases. *J Alzheimers Dis.* 2021;82:1067-1074.
57. Madeira C, Vargas-Lopes C, Brandao CO, et al. Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer's disease and depression. *Front Psychiatry.* 2018;9:561.
58. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. *Lancet Neurol.* 2012;11:1048-1056.
59. Hampel H, O'Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. *Nat Rev Neurol.* 2018;14:639-652.
60. Ibanez A, Parra MA, Butler C, Latin A, the Caribbean Consortium on D. The Latin America and the Caribbean Consortium on Dementia (LAC-CD): from networking to research to implementation science. *J Alzheimers Dis.* 2021;82:S379-S394.
61. Ibanez A, Yokoyama JS, Possin KL, et al. The multi-partner consortium to expand dementia Research in Latin America (ReDLat): driving multicentric research and implementation science. *Front Neurol.* 2021;12:631722.
62. Reyes-Pablo AE, Campa-Cordoba BB, Luna-Viramontes NI, et al. National dementia BioBank: a strategy for the diagnosis and study of neurodegenerative diseases in Mexico. *J Alzheimers Dis.* 2020;76:853-862.
63. Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. *Mol Psychiatry.* 2021;26:296-308.
64. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med.* 2020;26:387-397.
65. Khan TK, Alkon DL. Peripheral biomarkers of Alzheimer's disease. *J Alzheimers Dis.* 2015;44:729-744.
66. Ogonowski N, Salcidua S, Leon T, et al. Systematic review: microRNAs as potential biomarkers in mild cognitive impairment diagnosis. *Front Aging Neurosci.* 2021;13:807764.
67. Alawode DOT, Heslegrave AJ, Ashton NJ, et al. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. *J Intern Med.* 2021;290:583-601.
68. Wojsiat J, Laskowska-Kaszub K, Mietelska-Porowska A, Wojda U. Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach. *Biomark Med.* 2017;11:917-931.
69. O'Bryant SE, Mielke MM, Rissman RA, et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. *Alzheimers Dement.* 2017;13:45-58.
70. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol.* 2022;21:66-77.
71. Ashton NJ, Kiddle SJ, Graf J, et al. Blood protein predictors of brain amyloid for enrichment in clinical trials. *Alzheimers Dement (Amst).* 2015;1:48-60.
72. Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. *Alzheimers Res Ther.* 2019;11:76.
73. Slachevsky A, Zitko P, Martinez-Pernia D, et al. GERO Cohort Protocol, Chile, 2017-2022: community-based cohort of functional decline in subjective cognitive complaint elderly. *BMC Geriatr.* 2020;20:505.
74. Magaki S, Yong WH, Khanlou N, Tung S, Vinters HV. Comorbidity in dementia: update of an ongoing autopsy study. *J Am Geriatr Soc.* 2014;62:1722-1728.
75. Gullett JM, Albizu A, Fang R, et al. Baseline neuroimaging predicts decline to dementia from amnesic mild cognitive impairment. *Front Aging Neurosci.* 2021;13:758298.
76. Shiino A, Shirakashi Y, Ishida M, Tanigaki K, Japanese Alzheimer's Disease Neuroimaging I. Machine learning of brain structural biomarkers for Alzheimer's disease (AD) diagnosis, prediction of disease progression, and amyloid beta deposition in the Japanese population. *Alzheimers Dement (Amst).* 2021;13:e12246.
77. Zhou Y, Song Z, Han X, Li H, Tang X. Prediction of Alzheimer's disease progression based on magnetic resonance imaging. *ACS Chem Neurosci.* 2021;12:4209-4223.
78. Di Tella S, Cabinio M, Isernia S, et al. Neuroimaging biomarkers predicting the efficacy of multimodal rehabilitative intervention in the Alzheimer's Dementia Continuum Pathology. *Front Aging Neurosci.* 2021;13:735508.
79. Menon MC, Murphy B, Heeger PS. Moving biomarkers toward clinical implementation in kidney transplantation. *J Am Soc Nephrol.* 2017;28:735-7347.
80. Teunissen CE, Otto M, Engelborghs S, et al. White paper by the Society for CSF Analysis and Clinical Neurochemistry: overcoming barriers in biomarker development and clinical translation. *Alzheimers Res Ther.* 2018;10:30.
81. Bachli MB, Sedeno L, Ochab JK, et al. Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: a machine learning approach. *Neuroimage.* 2020;208:116456.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Parra MA, Orellana P, Leon T, et al. Biomarkers for dementia in Latin American countries: Gaps and opportunities. *Alzheimer's Dement.* 2023;19:721–735. <https://doi.org/10.1002/alz.12757>